Kario, Kazuomi
Katsuya, Tomohiro
Wada, Jun
Motoki, Hirohiko
Kuwahara, Koichiro
Tsujita, Kenichi
Taguchi, Takashi
Tanabe, Ayumi
Shimosawa, Tatsuo
Article History
Received: 27 March 2024
Revised: 1 July 2024
Accepted: 8 July 2024
First Online: 2 August 2024
Compliance with ethical standards
:
: K Kario received support for medical writing, article processing charges, research funding, and advisory fees from Daiichi Sankyo Co., Ltd.; grants from Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., MSD K.K., Sumitomo Pharma Co., Ltd., and Nippon Boehringer Ingelheim Co., Ltd.; consulting fees from Sanwa Chemical Co., Ltd.; honoraria from Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., and Viatris Inc.; and participated in advisory boards for Novartis Pharma K.K. and Daiichi Sankyo Co., Ltd. TK received honoraria from Daiichi Sankyo Co., Ltd., CureApp, Inc., and Novartis Pharma K.K. JW received honoraria for speakers’ bureaus from Astra Zeneca and Daiichi Sankyo. K Kuwahara received honoraria from Alnylam Japan K.K., Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., AstraZeneca K.K., Astellas Pharma Inc., Novo Nordisk Pharma Ltd., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma, K.K., Bayer Yakuhin, Ltd., and Pfizer Japan Inc.; research funding from Novo Nordisk Pharma Ltd. and Kowa Co., Ltd.; scholarships or donations from Otsuka Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Taisho Pharmaceutical Co., Ltd., and Fukuda Denshi Co., Ltd.; and departmental endowments from Abbott Medical Japan LLC., Medtronic Japan Co., Ltd., Biotronik Japan, Inc., Boston Scientific Japan K.K., Japan Lifeline Co., Ltd., Terumo Corporation, Nipro Corporation, and Cordis Japan G.K. KT received honoraria from Abbott Medical Co., Ltd., Amgen K.K., Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., Kowa Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Terumo Corporation; research funding from Mochida Pharmaceutical Co., Ltd. and EA Pharma Co., Ltd.; scholarships or donations from Abbott Medical Co., Ltd., ITI Co., Ltd., Boehringer Ingelheim Japan, Otsuka Pharmaceutical Co., Ltd., and Boston Scientific Japan K.K.; and departmental endowments from Abbott Japan Co., Ltd., Boston Scientific Japan K.K., Fides-one, Inc., GM Medical Co., Ltd., ITI Co., Ltd., Kaneka Medix Co., Ltd., Nipro Corporation, Terumo Co., Ltd., Philips Japan Ltd., Getinge Group Japan K.K., Orbusneich Medical K.K., Abbott Medical Co., Ltd., Biotronik Japan, Inc., Boston Scientific Japan K.K., Fukuda Denshi Co., Ltd., Japan Lifeline Co., Ltd., Medtronic Japan Co., Ltd., and Nippon Boehringer Ingelheim Co., Ltd. TS had an employment/leadership position/advisory role with Sekisui Medical Co., Ltd. and EP Mediate Co., Ltd.; and received honoraria from Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., Ion Retail Co., Ltd., and Ion Happicom Co., Ltd. TT and AT are employees of Daiichi Sankyo Co., Ltd., Tokyo, Japan. HM had no conflicts of interest to declare.